Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian…

Overview of attention for article published in BMC Cancer, December 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 27 Dimensions

Readers on

mendeley: 67 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 162 followers.

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. https://t.co/EaK3Nyc5TY

30 Dec 2018

Reply Repost Favourite